The epidemiology, pathogenesis and histopathology of fatty liver disease

Histopathology

Volumn 61, Issue 2, 2012, Pages 141-152

  Levene, Adam P ^a   Goldin, Robert D ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Alcoholic liver disease; Histopathology; Insulin resistance; Liver biopsy; Metabolic syndrome; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Steatosis

Indexed keywords

ADIPONECTIN; ALCOHOL; INSULIN; LEPTIN;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; APOPTOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FATTY LIVER; HEREDITY; HISTOPATHOLOGY; HISTORY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPOTOXICITY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ADIPOKINES; CYTOKINES; DIABETES COMPLICATIONS; FATTY LIVER; FATTY LIVER, ALCOHOLIC; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; OBESITY; OXIDATIVE STRESS; PREVALENCE; RISK FACTORS;

EID: 84864390922     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04145.x     Document Type: Review

References (102)

1. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am. J. Gastroenterol. 2007; 102; 399-408.
2. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129; 113-121.
3. Targher G, Bertolini L, Poli F et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54; 3541-3546.
4. Hamaguchi M, Kojima T, Takeda N et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J. Gastroenterol. 2007; 13; 1579-1584.
5. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41; 1313-1321.
6. Office for National Statistics. Death rates from alcohol-related diseases Available at
7. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40; 1387-1395.
8. Berasain C, Betes M, Panizo A et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 2000; 47; 429-435.
9. Wanless IR Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12; 1106-1110.
10. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42; 44-52.
11. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124; 71-79.
12. Speliotes EK, Massaro JM, Hoffmann U et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010; 51; 1979-1987.
13. Ioannou GN, Morrow OB, Connole ML, Lee SP. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology 2009; 50; 175-184.
14. Vitaglione P, Morisco F, Mazzone G et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology 2010; 52; 1652-1661.
15. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liver Dis. 2008; 28; 339-350.
16. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin. Liver Dis. 2007; 11; 1-16, vii.
17. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J. Hepatol. 2001; 35; 195-199.
18. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am. J. Gastroenterol. 1999; 94; 3010-3014.
19. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin. Liver Dis. 2004; 8; 521-533, viii.
20. Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44; 865-873.
21. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123; 134-140.
22. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36; 1349-1354.
23. Ratziu V, Bonyhay L, Di Martino V et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35; 1485-1493.
24. Shimada M, Hashimoto E, Taniai M et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 2002; 37; 154-160.
25. Bullock RE, Zaitoun AM, Aithal GP, Ryder SD, Beckingham IJ, Lobo DN. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J. Hepatol. 2004; 41; 685-686.
26. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54; 533-539.
27. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346; 987-990.
28. Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin. Liver Dis. 1988; 8; 12-25.
29. Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. Alcohol Res. Health 2003; 27; 209-219.
30. Phillips MG, Preedy VR, Hughes RD. Assessment of prognosis in alcoholic liver disease: can serum hyaluronate replace liver biopsy? Eur. J. Gastroenterol. Hepatol. 2003; 15; 941-944.
31. Stinson FS, Grant BF, Dufour MC. The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol. Clin. Exp. Res. 2001; 25; 1181-1187.
32. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999; 107; 450-455.
33. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998; 114; 842-845.
34. Day CP. Pathogenesis of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 2002; 16; 663-678.
35. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35; 373-379.
36. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999; 353; 1634-1636.
37. Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2006; 91; 4753-4761.
38. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 2006; 87; 1-16.
39. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am. J. Gastroenterol. 2006; 101; 2629-2640.
40. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006; 131; 934-945.
41. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259; 87-91.
42. Feldstein AE, Werneburg NW, Canbay A et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40; 185-194.
43. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37; 343-350.
44. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34; 1158-1163.
45. Miele L, Valenza V, La Torre G et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49; 1877-1887.
46. Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2001; 281; G1333-G1339.
47. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120; 1183-1192.
48. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004; 114; 147-152.
49. McClain CJ, Mokshagundam SP, Barve SS et al. Mechanisms of non-alcoholic steatohepatitis. Alcohol 2004; 34; 67-79.
50. George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J. Hepatol. 2003; 39; 756-764.
51. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999; 257; 79-83.
52. Kubota N, Terauchi Y, Yamauchi T et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 2002; 277; 25863-25866.
53. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40; 46-54.
54. Marra F, Aleffi S, Bertolani C, Petrai I, Vizzutti F. Adipokines and liver fibrosis. Eur. Rev. Med. Pharmacol. Sci. 2005; 9; 279-284.
55. Maeda N, Shimomura I, Kishida K et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002; 8; 731-737.
56. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 2003; 112; 91-100.
57. Ikejima K, Takei Y, Honda H et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122; 1399-1410.
58. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol. 2002; 37; 206-213.
59. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372; 425-432.
60. Feldstein AE, Canbay A, Angulo P et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125; 437-443.
61. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J. Hepatol. 2003; 39; 978-983.
62. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004; 39; 273-278.
63. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab. Invest. 2003; 83; 655-663.
64. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44; 27-33.
65. Anstee QM, Concas D, Kudo H et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J. Hepatol. 2010; 53; 542-550.
66. Mitry RR, De Bruyne R, Quaglia A, Hughes RD, Dhawan A. Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers. Hepatology 2007; 46; 2047-2048; author reply 2048.
67. Diab DL, Yerian L, Schauer P et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin. Gastroenterol. Hepatol. 2008; 6; 1249-1254.
68. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52; 894-903.
69. Diehl AM. Obesity and alcoholic liver disease. Alcohol 2004; 34; 81-87.
70. Albano E. Alcohol, oxidative stress and free radical damage. Proc. Nutr. Soc. 2006; 65; 278-290.
71. Dey A, Cederbaum AI. Alcohol and oxidative liver injury. Hepatology 2006; 43; S63-S74.
72. Ji C, Kaplowitz N. ER stress: can the liver cope? J. Hepatol. 2006; 45; 321-333.
73. Bardag-Gorce F, French BA, Nan L et al. CYP2E1 induced by ethanol causes oxidative stress, proteasome inhibition and cytokeratin aggresome (Mallory body-like) formation. Exp. Mol. Pathol. 2006; 81; 191-201.
74. Yuan GJ, Zhou XR, Gong ZJ, Zhang P, Sun XM, Zheng SH. Expression and activity of inducible nitric oxide synthase and endothelial nitric oxide synthase correlate with ethanol-induced liver injury. World J. Gastroenterol. 2006; 12; 2375-2381.
75. Bhopale KK, Wu H, Boor PJ, Popov VL, Ansari GA, Kaphalia BS. Metabolic basis of ethanol-induced hepatic and pancreatic injury in hepatic alcohol dehydrogenase deficient deer mice. Alcohol 2006; 39; 179-188.
76. Polavarapu R, Spitz DR, Sim JE et al. Increased lipid peroxidation and impaired antioxidant enzyme function is associated with pathological liver injury in experimental alcoholic liver disease in rats fed diets high in corn oil and fish oil. Hepatology 1998; 27; 1317-1323.
77. Fang C, Lindros KO, Badger TM, Ronis MJ, Ingelman-Sundberg M. Zonated expression of cytokines in rat liver: effect of chronic ethanol and the cytochrome P450 2E1 inhibitor, chlormethiazole. Hepatology 1998; 27; 1304-1310.
78. Neuman MG, Shear NH, Bellentani S, Tiribelli C. Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells. Gastroenterology 1998; 115; 157-166.
79. Keshavarzian A, Farhadi A, Forsyth CB et al. Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J. Hepatol. 2009; 50; 538-547.
80. Chen X, Sebastian BM, Nagy LE. Chronic ethanol feeding to rats decreases adiponectin secretion by subcutaneous adipocytes. Am. J. Physiol. Endocrinol. Metab. 2007; 292; E621-E628.
81. Naveau S, Perlemuter G, Chaillet M et al. Serum leptin in patients with alcoholic liver disease. Alcohol. Clin. Exp. Res. 2006; 30; 1422-1428.
82. Balasubramaniyan V, Viswanathan P, Nalini N. Effect of leptin administration on membrane-bound adenosine triphosphatase activity in ethanol-induced experimental liver toxicity. J. Pharm. Pharmacol. 2006; 58; 1113-1119.
83. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin. Liver Dis. 2008; 28; 386-395.
84. Sharma P, Martin DR, Pineda N et al. Quantitative analysis of T2-correction in single-voxel magnetic resonance spectroscopy of hepatic lipid fraction. J. Magn. Reson. Imaging 2009; 29; 629-635.
85. Brunt EM. Nonalcoholic steatohepatitis. Semin. Liver Dis. 2004; 24; 3-20.
86. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37; 1202-1219.
87. Nonalcoholic steatohepatitis clinical research network. Hepatology 2003; 37; 244.
88. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94; 2467-2474.
89. Caldwell S, Ikura Y, Dias D et al. Hepatocellular ballooning in NASH. J. Hepatol. 2010; 53; 719-723.
90. Levene AP, Goldin RD. Physiological hepatic nuclear vacuolation-how long does it persist? Histopathology 2010; 56; 426-429.
91. Banner BF, Savas L, Zivny J, Tortorelli K, Bonkovsky HL. Ubiquitin as a marker of cell injury in nonalcoholic steatohepatitis. Am. J. Clin. Pathol. 2000; 114; 860-866.
92. Zatloukal K, Stumptner C, Fuchsbichler A et al. p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am. J. Pathol. 2002; 160; 255-263.
93. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J. Hepatol. 2008; 48; 821-828.
94. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004; 40; 475-483.
95. Brunt EM, Kleiner DE, Wilson LA et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49; 809-820.
96. Everhart JE. Alcohol and hepatitis C: do we have a drinking problem? Gastroenterology 2006; 130; 1912-1914.
97. McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am. J. Gastroenterol. 1998; 93; 2022-2036.
98. Brunt EM. Histopathology of non-alcoholic fatty liver disease. Clin. Liver Dis. 2009; 13; 533-544.
99. Nonomura A, Enomoto Y, Takeda M et al. Clinical and pathological features of non-alcoholic steatohepatitis. Hepatol. Res. 2005; 33; 116-121.
100. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am. J. Gastroenterol. 1987; 82; 650-654.
101. Contos MJ, Cales W, Sterling RK et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001; 7; 363-373.
102. Sanderson SO, Smyrk TC. The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens. Am. J. Clin. Pathol. 2005; 123; 503-509.